




Quest Diagnostics
Circulating
Tumor DNA
Testing



Quest Diagnostics Circulating Tumor DNA Testing Instructions


[Home](#) » [Quest Diagnostics](#) » Quest Diagnostics Circulating Tumor DNA Testing Instructions

Contents

- 1 Quest Diagnostics Circulating Tumor DNA Testing
- 2 Product Information
- 3 Product Usage Instructions
- 4 Circulating Tumor DNA (ctDNA) Testing
- 5 Background
- 6 Methods and Results
- 7 Documents / Resources
 - 7.1 References
- 8 Related Posts



Quest Diagnostics Circulating Tumor DNA Testing



Product Information

Specifications

- **Product Name:** Circulating Tumor DNA (ctDNA) Testing Kit
- **Application:** Biomarker for minimal residual disease
- **Target Users:** Patients with colon cancer
- **Intended Use:** Guide treatment decisions in stage II colon cancer patients

Product Usage Instructions

Background

The ctDNA testing kit is designed to assist healthcare providers in determining the need for adjuvant chemotherapy (ACT) in stage II colon cancer patients. The kit detects circulating tumor DNA, which serves as a biomarker for minimal residual disease.

Methods and Results

Healthcare providers can use a decision-tree model to compare payer costs when deciding on ACT based on clinical evaluation only or clinical evaluation combined with ctDNA testing. The kit includes all necessary components for the collection and analysis of ctDNA.

Cost Savings

According to a study published in JAMA Health Forum, adopting ctDNA-guided treatment for colon cancer can lead to significant cost savings for both commercial health plans and Medicare Advantage plans. The first-year cost savings for both types of plans are outlined in the provided table.

Frequently Asked Questions (FAQ)

- **How does ctDNA testing impact payer budgets for patients with colon cancer?**

CtDNA testing can help reduce unnecessary adjuvant chemotherapy in stage II colon cancer patients, leading to cost savings for payers by avoiding the side effects of ACT.

- **Where can I find more information about Quest Diagnostics publications?**

For more information about Quest Diagnostics publications, please visit the Clinical Education Center.

Key Summary of Published Article

Circulating Tumor DNA (ctDNA) Testing

Payer cost savings



How does ctDNA testing affect payer budgets when used to guide treatment in patients with colon cancer?




Background

Post-surgical testing of ctDNA, a biomarker for minimal residual disease, can reduce unnecessary adjuvant chemotherapy (ACT) in stage II colon cancer patients, thus avoiding side effects of ACT. Since little is known about how ctDNA testing may affect the total cost of routine patient care, investigators compared payer budgets for scenarios in which ctDNA testing is adopted vs not adopted.



Methods and Results

A decision-tree model was developed to compare payer costs when ACT use is guided by (1) clinical evaluation only vs (2) clinical evaluation or ctDNA testing. Payer costs over 1 year, including cost of ctDNA testing and treatment, were assessed at various testing adoption rates. Costs were assessed for both commercial health and Medicare Advantage plans with 1 million covered members.




Compared to clinical evaluation only, adoption of ctDNA-guided treatment of colon cancer is projected to reduce costs for health plan payers.

1. Li Y, Heer AK, Sloane HS, et al. Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and Medicare Advantage plans. JAMA Health Forum. 2024;5(5):e241270. doi:10.1001/jamahealthforum.2024.1270

For more information about Quest Diagnostics publications, please visit the Clinical Education Center .

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. KS13078 05/2024

Documents / Resources



[Quest Diagnostics Circulating Tumor DNA Testing](#) [pdf] Instructions
Circulating Tumor DNA Testing, Tumor DNA Testing, DNA Testing, Testing

References

- [User Manual](#)

[Manuals+](#), [Privacy Policy](#)

This website is an independent publication and is neither affiliated with nor endorsed by any of the trademark owners. The "Bluetooth®" word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. The "Wi-Fi®" word mark and logos are registered trademarks owned by the Wi-Fi Alliance. Any use of these marks on this website does not imply any affiliation with or endorsement.